XNW28012 / Evopoint - LARVOL DELTA

Study of XNW28012 in Subjects With Metastatic Pancreatic Cancer Who Received Prior Systemic Therapy (clinicaltrials.gov) - P3 | N=226 | Recruiting | Sponsor: Evopoint Biosciences Inc.

New P3 trial • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor

Safety, efficacy, and pharmacokinetics of XNW28012, a tissue factor antibody-drug conjugate (ADC) with topoisomerase 1 inhibitor (TOP1i) payload, in patients with advanced solid tumors: Results from a phase I/II study. (ASCO 2026) - P1/2 | "XNW28012 demonstrated a manageable safety profile in heavily treated advanced solid tumor pts and promising anti-tumor activity in PDAC patients. The data support further development of XNW28012 in a broad range of solid tumors including PDAC. NC: Not Calculated."

ADC • Clinical • Metastases • P1/2 data • PK/PD data • Cervical Cancer • Conjunctivitis • Dental Disorders • Head and Neck Cancer • Heart Failure • Neutropenia • Ocular Infections • Ocular Inflammation • Oncology • Ophthalmology • Ovarian Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • Stomatitis

Phase I Open-Label Randomized Multicenter Study of XNW28012 Monotherapy in Metastatic Pancreatic Cancer (clinicaltrials.gov) - P1 | N=24 | Not yet recruiting | Sponsor: Evopoint Biosciences Inc.

Monotherapy • New P1 trial • Oncology • Pancreatic Cancer • Solid Tumor

Preclinical development of XNW28012, an antibody drug conjugate targeting tissue factor for treatment of solid tumors (AACR 2026) - "It is particularly important to note that XNW28012 has no toxic effect on the lungs and eyes, and no bleeding risk was observed in monkeys.Taken together, preclinical data suggest that XNW28012 could be a promising new antitumor agent for further investigation in clinical trials. Clinical activity of XNW28012 is currently under evaluation in a Phase I/II clinical trial (CTR20233056) and a Phase III clinical trial (CTR20252545)."

ADC • Preclinical • Cervical Cancer • Esophageal Cancer • Oncology • Ovarian Cancer • Pancreatic Cancer • Solid Tumor

Study of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (clinicaltrials.gov) - P1/2 | N=350 | Recruiting | Sponsor: Evopoint Biosciences Inc. | N=200 ➔ 350

Enrollment change • First-in-human • Cervical Cancer • Colorectal Cancer • Oncology • Ovarian Cancer • Pancreatic Cancer • Solid Tumor

Study of XNW28012 in Subjects with Advanced Solid Tumors Who Failed Standard Treatments (clinicaltrials.gov) - P1/2 | N=200 | Recruiting | Sponsor: Evopoint Biosciences Inc. | Not yet recruiting ➔ Recruiting | Initiation date: Mar 2025 ➔ Dec 2023

Enrollment open • Trial initiation date • Cervical Cancer • Hepatology • Oncology • Ovarian Cancer • Pancreatic Cancer • Solid Tumor

Study of XNW28012 in Subjects with Advanced Solid Tumors Who Failed Standard Treatments (clinicaltrials.gov) - P1/2 | N=200 | Not yet recruiting | Sponsor: Evopoint Biosciences Inc.

New P1/2 trial • Oncology • Solid Tumor